NM_004287.5:c.17A>G

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2

The NM_004287.5(GOSR2):​c.17A>G​(p.Gln6Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000114 in 1,550,018 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: š‘“ 0.000026 ( 0 hom., cov: 33)
Exomes š‘“: 0.00012 ( 4 hom. )

Consequence

GOSR2
NM_004287.5 missense

Scores

3
16

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:1

Conservation

PhyloP100: 2.96

Publications

0 publications found
Variant links:
Genes affected
GOSR2 (HGNC:4431): (golgi SNAP receptor complex member 2) This gene encodes a trafficking membrane protein which transports proteins among the medial- and trans-Golgi compartments. Due to its chromosomal location and trafficking function, this gene may be involved in familial essential hypertension. [provided by RefSeq, Mar 2016]
LRRC37A2 (HGNC:32404): (leucine rich repeat containing 37 member A2) Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022]
GOSR2-DT (HGNC:55346): (GOSR2 divergent transcript)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.01972729).
BP6
Variant 17-46923209-A-G is Benign according to our data. Variant chr17-46923209-A-G is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 462913.
BS2
High Homozygotes in GnomAdExome4 at 4 AR,Unknown gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GOSR2NM_004287.5 linkc.17A>G p.Gln6Arg missense_variant Exon 1 of 6 ENST00000640051.2 NP_004278.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GOSR2ENST00000640051.2 linkc.17A>G p.Gln6Arg missense_variant Exon 1 of 6 1 NM_004287.5 ENSP00000492751.1
ENSG00000262633ENST00000571841.1 linkn.17A>G non_coding_transcript_exon_variant Exon 1 of 10 5 ENSP00000461460.1

Frequencies

GnomAD3 genomes
AF:
0.0000263
AC:
4
AN:
152236
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000621
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000363
AC:
56
AN:
154194
AF XY:
0.000552
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000123
AC:
172
AN:
1397782
Hom.:
4
Cov.:
31
AF XY:
0.000193
AC XY:
133
AN XY:
689528
show subpopulations
āš ļø The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
African (AFR)
AF:
0.00
AC:
0
AN:
31588
American (AMR)
AF:
0.00
AC:
0
AN:
35702
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25162
East Asian (EAS)
AF:
0.00
AC:
0
AN:
35728
South Asian (SAS)
AF:
0.00211
AC:
167
AN:
79210
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
49166
Middle Eastern (MID)
AF:
0.000176
AC:
1
AN:
5686
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1077622
Other (OTH)
AF:
0.0000691
AC:
4
AN:
57918
āš ļø The allele balance in gnomAD4 Exomes is highly skewed from 0.5 (p-value = 0), which strongly suggests a high chance of mosaicism in these individuals.
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.393
Heterozygous variant carriers
0
9
19
28
38
47
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000263
AC:
4
AN:
152236
Hom.:
0
Cov.:
33
AF XY:
0.0000269
AC XY:
2
AN XY:
74376
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41464
American (AMR)
AF:
0.0000654
AC:
1
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5192
South Asian (SAS)
AF:
0.000621
AC:
3
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10628
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68044
Other (OTH)
AF:
0.00
AC:
0
AN:
2088
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.488
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000113
ExAC
AF:
0.000630
AC:
20

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Apr 06, 2018
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.Q6R variant (also known as c.17A>G), located in coding exon 1 of the GOSR2 gene, results from an A to G substitution at nucleotide position 17. The glutamine at codon 6 is replaced by arginine, an amino acid with highly similar properties. Based on data from gnomAD, the G allele has an overall frequency of approximately 0.038% (56/147100) total alleles studied. The highest observed frequency was 0.24% (55/22820) of South Asian alleles.This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Progressive myoclonic epilepsy Benign:1
Apr 22, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Benign
-0.41
T
BayesDel_noAF
Benign
-0.36
CADD
Uncertain
24
DANN
Uncertain
0.99
DEOGEN2
Benign
0.0098
.;.;.;.;.;.;T;.;.;.;.;.;.;.
Eigen
Benign
-0.084
Eigen_PC
Benign
0.082
FATHMM_MKL
Benign
0.47
N
LIST_S2
Benign
0.79
T;T;T;T;T;T;T;T;T;T;T;T;T;T
M_CAP
Benign
0.0077
T
MetaRNN
Benign
0.020
T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.4
.;.;.;L;.;.;L;.;L;.;.;.;.;.
PhyloP100
3.0
PrimateAI
Uncertain
0.57
T
PROVEAN
Benign
-0.33
.;.;.;N;N;.;.;.;.;.;.;.;.;.
REVEL
Benign
0.077
Sift
Uncertain
0.019
.;.;.;D;D;.;.;.;.;.;.;.;.;.
Sift4G
Benign
0.23
.;.;.;T;T;T;.;.;.;.;T;.;.;.
Polyphen
0.017, 0.0050
.;.;.;B;.;.;B;.;.;.;.;.;.;.
Vest4
0.29, 0.28, 0.21, 0.28
MutPred
0.38
Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);Gain of MoRF binding (P = 0.0084);
MVP
0.45
MPC
0.20
ClinPred
0.12
T
GERP RS
5.0
PromoterAI
0.070
Neutral
Varity_R
0.34
gMVP
0.27
Mutation Taster
=98/2
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs749270151; hg19: chr17-45000575; API